These results are what we hoped for when we first began developing this approach,' one researcher said. View on euronews ...

For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational ...

A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated ...

New research found that gene therapy for children with "bubble boy disease," or SCID, was successful in 95% of trial ...

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...

A groundbreaking gene therapy has successfully restored immune function in children with ADA-SCID, a severe genetic disorder.

Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the ...

“I remember asking the doctor if my daughter was going to die,” said Chelsea Oakley, mother of Cora Oakley, a newborn who was diagnosed with ADA-SCID when she was just seven days old, in April 2017.

ADA-SCID, or severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency, affects about 15 children each year in Europe. A child born with ADA-SCID is unable to fight off everyday ...

"Strimvelis returns home." With these words, Alessandro Aiuti, MD, PhD, head of the Pediatric Immunohematology Unit at the Scientific Institute for Research and Healthcare (IRCCS) San Raffaele ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S.

DUBLIN--(BUSINESS WIRE)--The "ADA-SCID - Competitive Landscape and Market Insight, 2018" report has been added to ResearchAndMarkets.com's offering. "ADA-SCID - Competitive Landscape and Market ...